Krystal Biotech
KRYS
13 hedge funds and large institutions have $31.3M invested in Krystal Biotech in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
32.6% more ownership
Funds ownership: 0% → 32.6% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.06M |
| 3 |
HCM
Highbridge Capital Management
New York
|
+$3.02M |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$3.02M |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
+$2.52M |
Top Sellers
KRYS Hedge Fund Activity: Q3 2017 in Review
13 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2017, worth a combined $31.3M.
Buyers outnumbered sellers: 13 funds opened new KRYS positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $12.1M.
- 13 institutional investors held Krystal Biotech (KRYS) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $31.3M of Krystal Biotech stock for Q3 2017.
- 13 funds opened new Krystal Biotech positions in Q3 2017 and 0 closed out, a net change of +13 holders.
- The largest Krystal Biotech buyer in Q3 2017 was Fidelity Investments, an estimated $12.1M added.
Based on aggregated 13F filings for Q3 2017.